J
Jerome Tamburini
Researcher at University of Paris
Publications - 151
Citations - 11002
Jerome Tamburini is an academic researcher from University of Paris. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 38, co-authored 135 publications receiving 9567 citations. Previous affiliations of Jerome Tamburini include Paris Descartes University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma
Mark A. Murakami,Alexandra N. Christodoulou,Amanda L. Christie,Tiffany DeSouza,Abner Louissaint,Una Vojinovic,Raphael Koch,Loretta S. Li,Scott P. Kallgren,Prakash Rao,Johannes Köster,Raga Vadhi,Eilene Duberow,Elizabeth A. Morgan,Hongjun Wang,Samia S. Ahmed,Katharine L. Majewski,Marina Konopleva,Jerome Tamburini,Alejandro Gutierrez,Michelle A. Kelliher,Julia Etchin,Irmela Jeremias,Irmela Jeremias,Andrew P. Weng,Andrew L. Kung,Andrew A. Lane,Francine Garnache-Ottou,Shai Izraeli,Eric N. Jacobsen,Ilene Galinsky,Richard Stone,Marian H. Harris,David M. Dorfman,Jon C. Aster,Henry W. Long,Lewis B. Silverman,Lewis B. Silverman,David M. Weinstock +38 more
TL;DR: The Public Repository of Xenografts (PRoXe), an established repository of PDX models of leukemia and lymphoma, is established and extensively annotated with patient-level information, including demographics, phase of treatment, prior therapies, tumor immunophenotye, cytogenetics, and molecular diagnostics.
Journal ArticleDOI
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Louis Perol,Eric Grignano,Adrien Contejean,Lauris Gastaud,Marielle Legoff,Patricia Franchi,Benedicte Deau-Fischer,Lise Willems,Didier Bouscary,Jerome Tamburini +9 more
TL;DR: B-cell acute lymphoblastic leukemia (B-ALL) can be cured in most children and in the majority of young adults with sufficiently intensive – and myelosuppressive – combination chemotherapy regimens.
Journal ArticleDOI
Hemophagocytic Lymphohistiocytosis Due to Acute Myeloid Leukemia Relapse: A Very Unusual Association
Maya Belhadj,Barbara Burroni,Felipe Suarez,Frédéric Pène,Nicolas Chapuis,Sylvain Pilorge,Lise Willems,Patricia Franchi,Bénédicte Deau,Didier Bouscary,Jerome Tamburini,Marielle Le Goff +11 more
TL;DR: It is suggested that the diagnostic of AML-related HLH should be promptly considered in front of unexplained fever, cytopenia, liver dysfunction or neurological symptoms as therapeutic intervention is urgent in this life-threatening situation.
Journal ArticleDOI
Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin.
Pierre-Edouard Debureaux,Delphine Le Febvre de Nailly,Emmanuelle Tavernier,Manel Bedoui,Frédérique Kuhnowski,Jerome Tamburini,Luc-Matthieu Fornecker,Vincent Camus,David Sibon,Marie-Pierre Moles,Sylvie Glaisner,Jean Philippe Richardet,Sébastien Mulé,Julien Calderaro,Daniel Azoulay,Jehane Fadlallah,Corinne Haioun,Jehan Dupuis +17 more
TL;DR: A national retrospective study of ASCT patients collected focusing on history of lymphoma, SOS risk factors, conditioning, diagnostic criteria for SOS, treatment of SOS, and outcomes, found that differential diagnoses (infections, treatment toxicity) were eliminated.
Journal ArticleDOI
Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse
Christian Recher,Xavier Thomas,Emmanuelle Tavernier,Bruno Lioure,Cécile Pautas,Aurore Perrot,Thorsten Braun,Thomas Cluzeau,Jean-Valère Malfuson,Jerome Tamburini,Céline Berthon,Alexis Magda,Chantal Himberlin,Stéphane de Botton,Edouard Randriamalala,Isabelle Plantier,Madalina Uzunov,Philippe Rousselot,Norbert Ifrah,Hervé Dombret,Nicolas Boissel +20 more
TL;DR: Younger patients with CBF-AML in first relapse had a high second complete remission rate regardless the intensive chemotherapy salvage, and in patients who received alloSCT, previous GO therapy significantly improved post-transplantation outcome.